Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: Results of a randomized, double-blind, parallel-group trial

International Clinical Psychopharmacology

Volumn 30, Issue 3, 2015, Pages 142-150

  Asadollahi, Shadi ^a   Heidari, Kamran ^b   Hatamabadi, Hamidreza ^b   Vafaee, Reza ^c,d   Yunesian, Somayeh ^b   Azadbakht, Alireza ^b   Mirmohseni, Ladan ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Agitation; Haloperidol; Psychotherapy; Randomized controlled trial; Therapeutics; Valproic acid

Indexed keywords

HALOPERIDOL; PLACEBO; VALPROIC ACID; NEUROLEPTIC AGENT; TRANQUILIZER;

ADULT; AGGRESSION; AGITATED BEHAVIOR SCALE; AGITATION ASSESSMENT; AGITATION CALMNESS EVALUATION SCALE; ALLERGIC REACTION; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMERGENCY HEALTH SERVICE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; VOMITING; BASAL GANGLIA DISEASES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PSYCHOLOGY; PSYCHOMOTOR AGITATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; VALPROIC ACID;

EID: 84927176852     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000064     Document Type: Article

References (57)

1. Allen MH (2000). Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry Suppl 14:11-20.
2. Allen MH, Carpenter D, Sheets JL, Miccio S, Ross R (2003). What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 9:39-58.
3. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists (2002). Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology 96:1004-1017.
4. Ayd Jr, Frank J (1978). Intravenous haloperidol therapy. Psychopharm Rev 13:20-23.
5. Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. (1997). Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15:335-340.
6. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. (2002). A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59:441-448.
7. Cañas F (2007). Management of agitation in the acute psychotic patient-efficacy without excessive sedation. Eur Neuropsychopharmacol Suppl 2: S108-S114.
8. Citrome L (2003). Schizophrenia and valproate. Psychopharmacol Bull Suppl 2:74-88.
9. Citrome L, Levine J, Allingham B (2000). Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 51:634-638.
10. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA (2004). Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr Serv 55:290-294.
11. Dolder C, McKinsey J (2010). Low-dose divalproex in agitated patients with Alzheimer's disease. J Psychiatr Pract 16:63-67.
12. Douglas PH, Block PC (2000). Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Catheter Cardiovasc Interv 50:352-355.
13. Dubin WR, Feld JA (1989). Rapid tranquilization of the violent patient. Am J Emerg Med 7:313-320.
14. Eli Lilly (2004). Comparisons of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia. Eli Lilly and Co Clinical Trial. Clinical Trials.Gov identifier NCT00088478.
15. Erler CJ, Thompson CB (2008). Part II: ethics, human rights, and clinical research. Air Med J 27:110-113.
16. Fisman DN, Harris AD, Sorock GS, Mittleman MA (2003). Sharps-related injuries in health care workers: a case-crossover study. Am J Med 114:688-694.
17. Gobbi G, Debonnel G (2003). What is a recommended treatment for aggression in a patient with schizophrenia? J Psychiatry Neurosci 28:320.
18. Gobbi G, Gaudreau PO, Leblanc N (2006). Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol 26:467-473.
19. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J (1999). Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 19:303-309.
20. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233.
21. Hilty DM, Rodriguez GD, Hales RE (1998). Intravenous valproate for rapid stabilization of agitation in neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 10:365-366.
22. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al. (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28:1186-1197.
23. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162:621-624.
24. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM (2001). The teratogenicity of anticonvulsant drugs. N Engl J Med 344:1132-1138.
25. Huf G, Coutinho ES, Adams CE. TREC-Rio trial (2002). TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. BMC Psychiatry 2:11.
26. Huf G, Coutinho ES, Adams CE. TREC Collaborative Group (2007). Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 335:869.
27. Janssen PA, Niemegeers CJ, Schellekens KH, Verbruggen FJ, Van Nueten JM (1963). The pharmacology of dehydrobenzperidol, a new potent and short acting neuroleptic agent chemically related to Haloperidol. Arzneimittelforschung 13:205-211.
28. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
29. King DJ, Burke M, Lucas RA (1995). Antipsychotic drug-induced dysphoria. Br J Psychiatry 167:480-482.
30. Kunen S, Niederhauser R, Smith PO, Morris JA, Marx BD (2005). Race disparities in psychiatric rates in emergency departments. J Consult Clin Psychol 73:116-126.
31. Lindenmayer JP (2000). The pathophysiology of agitation. J Clin Psychiatry Suppl 14:5-10.
32. Lindenmayer JP, Kotsaftis A (2000). Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 61:123-128.
33. Lonergan ET, Cameron M, Luxenberg J (2004). Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2:CD003945.
34. Lukens TW, Wolf SJ, Edlow JA, Shahabuddin S, Allen MH, Currier GW, Jagoda AS. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department (2006). Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 47:79-99.
35. McAllister-Williams RH, Ferrier IN (2002). Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 180:485-489.
36. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. (2001). A doubleblind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21:389-397.
37. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ (2010). The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 5:E8-E16.
38. National Collaborating Centre for Nursing and Supportive Care (UK) (2005). Violence: the short-term management of disturbed/violent behaviour in inpatient psychiatric settings and emergency departments. London: Royal College of Nursing (UK).
39. Nelson RJ, Chiavegatto S (2001). Molecular basis of aggression. Trends Neurosci 24:713-719.
40. NHS (2004). Newer drugs for epilepsy in adults. London: National Institute for Clinical Excellence (NICE). NICE Technology Appraisal 76. http://www.nice. org.uk/guidance/ta76. [Accessed 3 December 2014].
41. Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, et al. (2001). Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 9:58-66.
42. Post RM, Weiss SR, Chuang DM (1992). Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 12 (Suppl):23S-35S.
43. Pratt P, Chandler-Oatts J, Nelstrop L, Branford D, Periera S, Johnston S (2008). Establishing gold standard approaches to rapid tranquillisation: review and discussion of the evidence of the safety and efficacy of medications used. J Psychiatr Intensive Care 4:43-57.
44. Royal College of Psychiatrists Psychopharmacology Sub-Group (1997). The association between antipsychotic drugs and sudden death. Council Report CR57. London: Royal College of Psychiatrists.
45. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME (2005). Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 62:37-45.
46. Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, Thayer S (1991). Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52:177-180.
47. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P (2002). Sodium valproate in the treatment of aggressive behavior in patients with dementia - a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 17:579-585.
48. Spivey WH, Abramson NS, Iserson KV, MacKay CR, Cohen MP (1991). Informed consent for biomedical research in acute care medicine. Ann Emerg Med 20:1251-1265.
49. Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, et al. (2005). Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 13:942-949.
50. Tesar GE (1993). The agitated patient, Part I: evaluation and behavioral management. Hosp Community Psychiatry 44:329-331.
51. Thomas H Jr, Schwartz E, Petrilli R (1992). Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med 21:407-413.
52. Tisdale JE, Kovacs R, Mi D, McCabe GP, Cariera BL, Sharma N, Rosman H (2007). Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol. Pharmacotherapy 27:175-182.
53. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA (2007). Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68:111-119.
54. Vance H, Kauffman C, Miller B, Mansour T (2003). Treatment of agitation using Depakote: a patient with dementia. Psychiatry 66:358-359.
55. Yildiz A, Sachs GS, Turgay A (2003). Pharmacological management of agitation in emergency settings. Emerg Med J 20:339-346.
56. Zimbroff DL (2003). Management of acute psychosis: from emergency to stabilization. CNS Spectr 8 (Suppl 2):10-15.
57. Zun LS, Downey LV (2008). Level of agitation of psychiatric patients presenting to an emergency department. Prim Care Companion J Clin Psychiatry 10:108-113.